antigenemia

(redirected from antigenaemia)
Also found in: Encyclopedia.

antigenemia

 [an″tĭ-jĕ-ne´me-ah]
the presence of antigen, such as hepatitis B surface antigen, in the blood.

an·ti·ge·ne·mi·a

(an'ti-jĕ-nē'mē-ă),
Persistence of antigen in circulating blood; for example, HBs-antigenemia (presence of hepatitis B virus surface antigen in blood serum).
[antigen + G. haima, blood]

an·ti·ge·ne·mi·a

(an'ti-jĕ-nē'mē-ă)
Persistence of antigen in circulating blood, such as HBs-antigenemia (presence of hepatitis B virus surface antigen in serum).
Synonym(s): antigenaemia.
[antigen + G. haima, blood]
References in periodicals archive ?
A laboratory dashboard for CrAg has been integrated into a broader SA HIV programme dashboard, with two key indicators: CrAg screening coverage and prevalence of cryptococcal antigenaemia. Good linkage to laboratory CrAg results is the cornerstone of this programme.
Hence, this prompted the study which aims at finding occurrence of and risk factors associated with Cryptococcal antigenaemia in ART naive patients with HIV.
Laboratory evidence of CMV infection was confirmed by the following tests: CMV PCR (n=136), CMV pp65 antigenaemia test (n=15), CMV viral culture (n=9), and CMV serology (n=4).
HIV-infected adults with a [CD4.sup.+] T-lymphocyte count <100 cells/[micro]l are recommended to be screened for cryptococcal antigenaemia. If screening is initiated by a clinician (medical practitioner or nurse trained in nurse-initiated management of ART (NIMART)) and not performed reflexively in the laboratory, then the expert panel recommends that screening be restricted to: ART-naive adults with [CD4.sup.+]T-lymphocyte count <100 cells/[micro]l and no prior CM.
Filarial antigenaemia was low and continued to decrease significantly in the age group 15-25 years in villages receiving MDA+VC in contrast to villages receiving only MA.
However, there was no significant difference in antigenaemia levels between pre-treatment (day 0) and PT samples collected on day 7 onwards till day 365.
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.